[Evaluation of the therapeutic efficacy of XXXX in @entity10217 ]

@entity1 @entity10217 @entity149 @entity619 @entity413
OBJECTIVE: To evaluate the efficacy of @entity619 as an auxiliary therapeutic tool to the antibiotics in hospitalized @entity1 with @entity10217 . METHODS: A retrospective clinical comparative study was undertaken with @entity1 from a pediatric ward affected by laboratory proved @entity10217 at a university hospital. Cases of @entity1 in state of shock at admission or deceased in the first 24 hours were excluded. During the period from 1987 to 1989 33 @entity1 were treated only with antibiotics (group A), while from 1990 to 1993 other 66 @entity1 received additionally @entity619 (12mg/m2/24h) by intravenous route during four days beginning at the admission to the hospital (group B). The two groups were evaluated at baseline through prognostic scores and analysis of their clinical and laboratorial characteristics obtained from data recorded at the admission. The parameters to evaluate @entity619 efficacy were the comparative number of @entity149 detected at the hospital, and the liquoric profile (leukocyte count, @entity413 and protein content) verified between day 9 and day 11 of hospitalization. RESULTS: The profile of the two groups (A and B) were homogeneously evaluated by the illness severity scores and their clinical and laboratorial characteristics. Nine complications were recognized in group A (27.2%) and 21 (31.8%) among those of group B, difference not significant. Likewise, there were not observed liquoric differences between the two groups related to the chimiocytologic pattern. CONCLUSIONS: No effect of @entity619 therapy to prevent neurologic and @entity10217 was observed during hospitalization. Similarly no favorable effect in relation to the liquoric pattern verified between day 9 and day 11 of hospitalization was recognized.
